A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

摘要: 1 Background: Serum CA125 often rises several months before women with OC have symptoms or clinical signs of relapse. OV05/55955 was designed to determine whether there were benefits from early treatment based on a confirmed elevation levels versus delaying until clinically indicated. Methods: Women in complete remission after first-line platinum-based chemotherapy and normal registered. measured every 3 but patients investigators blinded the results, which only monitored by trials units. If exceeded twice upper limit normal, randomized either immediate remain having measurements commencing when symptomatic recurrence appeared. Patients both arms treated according standard local practice. The primary outcome measure overall survival. study detect 10% improvement 2-year survival in...